2026-06-01T08:50:52Zhttps://riubu.ubu.es/oai/request

oai:riubu.ubu.es:10259/88122024-03-14T11:52:33Zcom_10259_4219com_10259_5086com_10259_2604col_10259_4220

Standaert, David G. 6da922f3-858b-4e9f-9899-3e00594a5650 600 Aldred, Jason 3efc0f48-3958-4907-ae8f-c3b0f11b415f 600 Anca-Herschkovitsch, Marieta e1a4479e-6471-49b3-92d2-17279109f9d7 600 Bourgeois, Paul b487d6bc-0f84-4b8f-818a-2240c88e3a5f 600 Cubo Delgado, Esther 131 600 0000-0003-0018-1182 Davis, Thomas L. e3f0ce6d-083c-4b71-a06a-59a170e7e077 600 Iansek, Robert c3e67ffe-d7fd-4cc4-8e0b-713fd18e398a 600 Kovács, Norbert 149d8665-cabe-4e26-8309-242f580acc9c 600 Pontieri, Francesco E. 0e19bd2c-02a2-4948-84bf-c05c0f7c94c8 600 Siddiqui, Mustafa S. 1ac8fffa-db1e-4ee2-8a6d-0461cd702bcc 600 Simu, Mihaela c804cd12-7b9d-499a-823a-f929b9eb69f2 600 Bergmann, Lars 39398a25-ebc2-4008-b8c7-be0c8426ad38 600 Kukreja, Pavnit 310f6280-4048-40e8-a3ad-51110ca1805b 600 Robieson, Weining 8b327a37-7971-4e04-910d-ffb34f40484e 600 Chaudhuri, K. Ray 9c6dffc7-c13f-407e-b690-89052e59d909 600 2024-03-12T13:20:52Z 2024-03-12T13:20:52Z 2021-05 2330-1619 http://hdl.handle.net/10259/8812 10.1002/mdc3.13239 2330-1619 Background:Levodopa-carbidopa intestinal gel (LCIG) is an established treatment for improvingmotor and some non-motor symptoms (NMS) in patients with advanced Parkinson’s disease (PD). Prospectivelong-term data in routine clinical practice are limited.ObjectiveObjective:Assess LCIG effectiveness and safety in patients with advanced PD after 12 months during real-worldroutine clinical practice.MethodsMethods:Duodopa/Duopa in patients with advanced Parkinson’s disease—a global observational studyevaluating long-term effectiveness (DUOGLOBE) (NCT02611713) is an ongoing, prospective, multinational,observational study of LCIG-naïve patients treated as part of routine clinical practice; 3 years of follow-up areplanned. The primary outcome is the change in patient-reportedofftime. Other assessments include theUnified Dyskinesia Rating Scale (UDysRS), Non-Motor Symptoms Scale (NMSS), Parkinson’s Disease Sleep scale(PDSS-2), Epworth Sleepiness Scale (ESS), health-related quality of life (HR-QoL), caregiver burden, and seriousadverse events (SAEs). Outcomes from baseline to month (M) 12 are presented.ResultsResults:In this 12-month follow-up, patients (N=195) had baseline characteristics similar to other LCIG studies.Significant improvements (mean change to M12) were observed inofftime ( 3.9 3.6 hr/day,P< 0.001),dyskinesia assessed using the UDysRS ( 9.6 22.5,P< 0.001), NMSS ( 23.1 41.4,P< 0.001), sleep andsleepiness symptoms on the PDSS-2 ( 6.5 12.2,P< 0.001) and ESS ( 1.0 5.7,P< 0.05), HR-QoL ( 9.0 21.6,P< 0.001), and caregiver burden ( 1.9 6.7,P=0.008). Overall, 40.5% (n=79) of patients experienced SAEs;fall (n=6; 3.1%) and urinary tract infection (n=6; 3.1%) were SAEs reported in≥3% of patients.ConclusionsConclusions:These 12-month outcome data show sustained, long-term improvements and support the real-world effectiveness of LCIG in patients with advanced PD. Safety was consistent with previous studies. application/pdf eng International Parkinson and Movement Disorder Society Movement Disorders Clinical Practice. 2021, V. 8, n. 7, p. 1061-1074 https://doi.org/10.1002/mdc3.13239 Attribution-NonCommercial-NoDerivatives 4.0 Internacional http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess DUOGLOBE Parkinson’s disease Levodopa-carbidopa intestinal gel Dyskinesia Real-world data Sistema nervioso-Enfermedades Medicina Neurología Nervous system-Diseases Medicine Neurology DUOGLOBE: One‐Year Outcomes in a Real‐World Study of Levodopa Carbidopa Intestinal Gel for Parkinson's Disease info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Movement Disorders Clinical Practice 8 7 1061 1074 THUMBNAIL Standaert-mdcp_2021.pdf.jpg Standaert-mdcp_2021.pdf.jpg IM Thumbnail image/jpeg 3854 https://riubu.ubu.es/bitstream/10259/8812/4/Standaert-mdcp_2021.pdf.jpg f9a3750b172d2fea447cef0c122691bd MD5 4 LICENSE license.txt license.txt text/plain; charset=utf-8 999 https://riubu.ubu.es/bitstream/10259/8812/3/license.txt b295bcbce42e2caabeb0c623d3860c06 MD5 3 CC-LICENSE license_rdf license_rdf application/rdf+xml; charset=utf-8 805 https://riubu.ubu.es/bitstream/10259/8812/2/license_rdf 4460e5956bc1d1639be9ae6146a50347 MD5 2 ORIGINAL Standaert-mdcp_2021.pdf Standaert-mdcp_2021.pdf application/pdf 744328 https://riubu.ubu.es/bitstream/10259/8812/1/Standaert-mdcp_2021.pdf 8a077884bc24f5d4737f6a52c66828af MD5 1 10259/8812 oai:riubu.ubu.es:10259/8812 2024-03-14 12:52:33.133 Repositorio Institucional de la Universidad de Burgos bubrep@ubu.es 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